Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Severe Plaque Psoriasis
Conditions
Moderate to Severe Plaque Psoriasis
Trial Timeline
Mar 25, 2021 → Aug 27, 2025
NCT ID
NCT04566666About Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3) is a phase 2 stage product being developed by Sun Pharmaceutical for Moderate to Severe Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT04566666. Target conditions include Moderate to Severe Plaque Psoriasis.
What happened to similar drugs?
6 of 20 similar drugs in Moderate to Severe Plaque Psoriasis were approved
Approved (6) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04566666 | Phase 2 | Completed |
Competing Products
20 competing products in Moderate to Severe Plaque Psoriasis